TRxADE HEALTH, INC. Files 10-Q for Period Ending September 30, 2023

TL;DR

<b>TRxADE HEALTH, INC. filed its quarterly report (10-Q) for the period ending September 30, 2023, detailing its financial status and operations.</b>

AI Summary

TRxADE HEALTH, INC (SCNX) filed a Quarterly Report (10-Q) with the SEC on January 16, 2024. TRxADE HEALTH, INC. filed a 10-Q report for the period ending September 30, 2023. The company's fiscal year ends on December 31. TRxADE HEALTH, INC. is incorporated in Delaware. The company's principal business address is 2420 Brunello Trace, Lutz, FL 33558. The filing was made on January 16, 2024.

Why It Matters

For investors and stakeholders tracking TRxADE HEALTH, INC, this filing contains several important signals. This filing provides investors and analysts with the latest financial performance data for TRxADE HEALTH, INC. for the third quarter of 2023. Understanding the details within this 10-Q is crucial for assessing the company's current financial health, operational efficiency, and future prospects.

Risk Assessment

Risk Level: low — TRxADE HEALTH, INC shows low risk based on this filing. The filing is a standard 10-Q, providing routine financial disclosures without immediate red flags or significant new information that would alter the risk profile.

Analyst Insight

Review the detailed financial statements and management's discussion and analysis within the 10-Q to identify any trends or specific performance indicators.

Key Numbers

• 2023-09-30 — Period of Report (Conformed period of report)
• 2024-01-16 — Filing Date (Date the filing was made)
• 1231 — Fiscal Year End (Company's fiscal year end)
• DE — State of Incorporation (State where the company is incorporated)

Key Players & Entities

• TRxADE HEALTH, INC. (company) — Filer and subject of the report
• 2023-09-30 (date) — Period of report
• 2024-01-16 (date) — Filing date
• 2420 BRUNELLO TRACE (address) — Business and mailing address
• LUTZ (location) — City of business and mailing address
• FL (location) — State of business and mailing address
• 33558 (postal_code) — ZIP code of business and mailing address
• 1934 Act (regulation) — SEC Act under which the filing is made

FAQ

Industry Context

TRxADE HEALTH operates within the wholesale drug and druggists' sundries sector, a segment of the broader healthcare and pharmaceutical distribution industry.

Regulatory Implications

The filing is made under the Securities Exchange Act of 1934, requiring public companies to submit regular financial disclosures to the SEC.

What Investors Should Do

1. Analyze the financial statements for revenue, expenses, and profitability trends.
2. Review the Management's Discussion and Analysis (MD&A) section for insights into operational performance and future outlook.
3. Check for any significant changes in liabilities or equity structure compared to previous filings.

Key Dates

• 2023-09-30: Quarter End — End of the reporting period for the 10-Q
• 2024-01-16: Filing Date — Date the 10-Q was officially submitted to the SEC

Year-Over-Year Comparison

This is the initial 10-Q filing for the period ending September 30, 2023, following the previous reporting periods.

Key Financial Figures

• $0.00001 — nge on which registered Common Stock, $0.00001 Par Value Per Share MEDS The NASDAQ

Filing Documents

• form10-q.htm (10-Q) — 1462KB
• ex31-1.htm (EX-31.1) — 18KB
• ex31-2.htm (EX-31.2) — 18KB
• ex32-1.htm (EX-32.1) — 8KB
• ex32-2.htm (EX-32.2) — 8KB
• form10-q_001.jpg (GRAPHIC) — 7KB
• form10q_003.jpg (GRAPHIC) — 2KB
• 0001493152-24-002429.txt (&nbsp;) — 7768KB
• meds-20230930.xsd (EX-101.SCH) — 67KB
• meds-20230930_cal.xml (EX-101.CAL) — 80KB
• meds-20230930_def.xml (EX-101.DEF) — 301KB
• meds-20230930_lab.xml (EX-101.LAB) — 509KB
• meds-20230930_pre.xml (EX-101.PRE) — 393KB
• form10-q_htm.xml (XML) — 1209KB

: FINANCIAL INFORMATION

PART I: FINANCIAL INFORMATION 4

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS 4

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 26

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 36

CONTROLS AND PROCEDURES

ITEM 4. CONTROLS AND PROCEDURES 36

OTHER INFORMATION

PART II. OTHER INFORMATION 38

LEGAL PROCEEDINGS

ITEM 1. LEGAL PROCEEDINGS 38

RISK FACTORS

ITEM 1A. RISK FACTORS 38

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 41

DEFAULTS UPON SENIOR SECURITIES

ITEM 3. DEFAULTS UPON SENIOR SECURITIES 41

MINE SAFETY DISCLOSURES

ITEM 4. MINE SAFETY DISCLOSURES 41

OTHER INFORMATION

ITEM 5. OTHER INFORMATION 41

EXHIBITS

ITEM 6. EXHIBITS 42 2 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (" Report "), including without limitation, " Management's Discussion and Analysis of Financial Condition and Results of Operations, " contains forward-looking statements, within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995, regarding future events and the future results of the Company that are based on current expectations, estimates, forecasts, and projections about the industry in which the Company operates and the beliefs and assumptions of the management of the Company. Words such as " expects, " " anticipates, " " targets, " " goals, " " projects, " " intends, " " plans, " " believes, " " seeks, " " estimates, " variations of such words, and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are only predictions and are subject to risks, uncertainties and assumptions that are difficult to predict. These factors include, but are not limited to: Our limited amount of cash; The negative effect on our business and our ability to raise capital that is created by the fact that there is a substantial doubt about our ability to continue as a going concern; Risks of our operations not being profitable; Claims relating to alleged violations of intellectual property rights of others; Technical problems with our websites; Risks relating to implementing our acquisition strategies; Negative effects on our operations associated with the opioid pain medication health crisis; Regulatory and licensing requirement risks; Risks related to changes in the U.S. healthcare environment; The status of our information systems, facilities and distribution networks; Risks associated with the operations of our more established competitors; Regulatory changes; Healthcare fraud; The potential impact of some future pandemic; Inf

View Full Filing

View this 10-Q filing on SEC EDGAR